LadRx Corporation (LADX) Research

LadRx Corporation is a biopharmaceutical firm dedicated to researching and developing innovative treatments for cancer patients. Its flagship compound, aldoxorubicin, an advanced drug conjugate derived from the established chemotherapy agent doxorubicin, is currently undergoing late-stage clinical evaluation. Additionally, its pipeline includes several early-stage drug candidates, specifically linker-activated drug releases 7, 8, 9, and 10, all designed to combat various forms of cancer. Previously known as CytRx Corporation, the company adopted the name LadRx Corporation in September 2022. Established in 1985, LadRx Corporation operates from its main offices in Los Angeles, California.

Market snapshot

Symbol
LADX
Price
$0.11
Day change
+872.73%
Market cap
$53.0K
P/E ratio
-0.14x
52-week range
0.01-2.4
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Acro Biomedical Co., Ltd. (ACBM)
  • Biome Grow Inc. (BIOIF)
  • DNAPrint Genomics, Inc. (DNAG)
  • Instadose Pharma Corp. (INSD)
  • Medivolve Inc. (MEDVF)
  • Manhattan Scientifics, Inc. (MHTX)
  • Mera Pharmaceuticals, Inc. (MRPI)
  • Nanobac Pharmaceuticals, Incorporated (NNBP)

Recent insider activity

  • Caldwell Joel K — A-Award (5000 shares) on 2024-01-15
  • Claiborne Cary J — A-Award (5000 shares) on 2024-01-15
  • Simpson Jennifer K. — A-Award (5000 shares) on 2024-01-15
  • CALOZ JOHN Y — A-Award (15000 shares) on 2024-01-15
  • Snowdy Stephen — A-Award (25000 shares) on 2024-01-15

Open LadRx Corporation (LADX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.